Overview

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Are Naive to Biologic DMARD Therapy

Status:
Terminated

Trial end date:
2021-05-11

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate the effect of filgotinib compared to placebo as assessed by the American College of Rheumatology 20% improvement (ACR20) response in participants with active psoriatic arthritis who are naive to biologic disease-modifying anti-rheumatic drug (DMARD) therapy. The study consists of two parts, the Main Study and the Long Term Extension (LTE).

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Collaborator:

Galapagos NV

Treatments:

Adalimumab